Monday, February 13, 2017 10:53:52 PM
In December 2014, the Company entered into an equity offering sales agreement, or the 2014 Sales Agreement, with Cantor Fitzgerald. Under the terms of the 2014 Sales Agreement, the Company may offer and sell shares of its common stock, from time to time, through the investment bank in at-the-market offerings. During the three and nine months ended December 31, 2015, the Company issued no shares of common stock in at-the-market offerings under the 2014 Sales Agreement. During the three and nine months ended December 31, 2016, the Company issued zero and 997,181 shares of common stock in at-themarket offerings under the 2014 Sales Agreement with net proceeds of approximately $4.5 million during the nine months ended December 31, 2016, after deducting underwriting discounts and commissions and expenses payable by the Company.
IMPORTANT PART - As of December 31, 2016, the Company has sold an aggregate of 1,997,181 shares of common stock in at-the-market offerings under the 2014 Sales Agreement, with net proceeds of approximately $10.8 million. On July 20, 2016, the Company filed a prospectus supplement to move the remaining shares of common stock that previously could have been sold pursuant to the 2014 Sales Agreement under the 2013 Shelf to the 2015 Shelf, which does not expire until March 17, 2018. Based on sales through December 31, 2016, the Company can sell an additional $21.9 million of shares pursuant to the 2014 Sales Agreement under the 2015 Shelf. - *** Basically, @ $3.00/share ONVO has the right to sell an additional 7.3mm shares of common stock to the public. This right to sell lasts until March 17, 2018. Therefore, the lower the stock price falls the more shareholders will be diluted by this right to sell $21.9mm worth of common stock
Recent ONVO News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/18/2024 08:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:01:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:05:26 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/26/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:05:07 PM
- Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis • GlobeNewswire Inc. • 07/16/2024 12:05:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/31/2024 08:05:33 PM
- Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease • GlobeNewswire Inc. • 05/21/2024 12:05:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/14/2024 04:45:20 PM
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) • GlobeNewswire Inc. • 05/14/2024 03:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 09:00:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/10/2024 09:15:22 PM
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering • GlobeNewswire Inc. • 05/09/2024 12:00:12 AM
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo • GlobeNewswire Inc. • 04/15/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:56:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:05:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/26/2024 10:09:03 PM
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/25/2024 01:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM